Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1985 1
1986 1
1987 1
1989 1
1995 1
1996 1
1998 1
2000 1
2002 1
2003 1
2004 1
2005 7
2006 3
2008 6
2009 12
2010 13
2011 17
2012 20
2013 15
2014 9
2015 12
2016 11
2017 7
2018 7
2019 13
2020 20
2021 17
2022 13
2023 17
2024 16
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

222 results

Results by year

Filters applied: . Clear all
Page 1
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study.
Granit V, Benatar M, Kurtoglu M, Miljković MD, Chahin N, Sahagian G, Feinberg MH, Slansky A, Vu T, Jewell CM, Singer MS, Kalayoglu MV, Howard JF Jr, Mozaffar T; MG-001 Study Team. Granit V, et al. Lancet Neurol. 2023 Jul;22(7):578-590. doi: 10.1016/S1474-4422(23)00194-1. Lancet Neurol. 2023. PMID: 37353278 Free PMC article. Clinical Trial.
FINDINGS: We recruited 16 individuals for screening between Jan 7, 2020 and Aug 3, 2022. 14 participants were enrolled (n=3 in part 1, n=11 in part 2). Ten participants were women and four were men. Two individuals did not qualify due to low baseline MG-ADL score ( …
FINDINGS: We recruited 16 individuals for screening between Jan 7, 2020 and Aug 3, 2022. 14 participants were enrolled (n=3 in part 1 …
IL-15 in the Combination Immunotherapy of Cancer.
Waldmann TA, Dubois S, Miljkovic MD, Conlon KC. Waldmann TA, et al. Front Immunol. 2020 May 19;11:868. doi: 10.3389/fimmu.2020.00868. eCollection 2020. Front Immunol. 2020. PMID: 32508818 Free PMC article. Review.
Aortic Valve Replacement Versus Conservative Treatment in Asymptomatic Severe Aortic Stenosis: The AVATAR Trial.
Banovic M, Putnik S, Penicka M, Doros G, Deja MA, Kockova R, Kotrc M, Glaveckaite S, Gasparovic H, Pavlovic N, Velicki L, Salizzoni S, Wojakowski W, Van Camp G, Nikolic SD, Iung B, Bartunek J; AVATAR Trial Investigators*. Banovic M, et al. Circulation. 2022 Mar;145(9):648-658. doi: 10.1161/CIRCULATIONAHA.121.057639. Epub 2021 Nov 13. Circulation. 2022. PMID: 34779220 Free article. Clinical Trial.
RESULTS: Between June 2015 and September 2020, 157 patients (mean age, 67 years; 57% men) were randomly allocated to early surgery (n=78) or conservative treatment (n=79). Follow-up was completed in May 2021. Overall median follow-up was 32 months: 28 months in the …
RESULTS: Between June 2015 and September 2020, 157 patients (mean age, 67 years; 57% men) were randomly allocated to early surgery (n …
International real-world study of DLL3 expression in patients with small cell lung cancer.
Rojo F, Corassa M, Mavroudis D, Öz AB, Biesma B, Brcic L, Pauwels P, Sailer V, Gosney J, Miljkovic D, Hader C, Wu M, Almarez T, Penault-Llorca F. Rojo F, et al. Lung Cancer. 2020 Sep;147:237-243. doi: 10.1016/j.lungcan.2020.07.026. Epub 2020 Jul 27. Lung Cancer. 2020. PMID: 32745892 Free article.
DLL3 expression concordance was 88 % between paired specimens (n = 17; Cohen's kappa P value, .9412). There was no significant difference in median overall survival from SCLC diagnosis for evaluable patients with nonmissing data based on DLL3 expression (negative DLL3 expr …
DLL3 expression concordance was 88 % between paired specimens (n = 17; Cohen's kappa P value, .9412). There was no significant differ …
Epidemiology of myosteatosis.
Miljkovic I, Zmuda JM. Miljkovic I, et al. Curr Opin Clin Nutr Metab Care. 2010 May;13(3):260-4. doi: 10.1097/MCO.0b013e328337d826. Curr Opin Clin Nutr Metab Care. 2010. PMID: 20179586 Free PMC article. Review.
Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy.
Revach OY, Cicerchia AM, Shorer O, Petrova B, Anderson S, Park J, Chen L, Mehta A, Wright SJ, McNamee N, Tal-Mason A, Cattaneo G, Tiwari P, Xie H, Sweere JM, Cheng LC, Sigal N, Enrico E, Miljkovic M, Evans SA, Nguyen N, Whidden ME, Srinivasan R, Spitzer MH, Sun Y, Sharova T, Lawless AR, Michaud WA, Rasmussen MQ, Fang J, Palin CA, Chen F, Wang X, Ferrone CR, Lawrence DP, Sullivan RJ, Liu D, Sachdeva UM, Sen DR, Flaherty KT, Manguso RT, Bod L, Kellis M, Boland GM, Yizhak K, Yang J, Kanarek N, Sade-Feldman M, Hacohen N, Jenkins RW. Revach OY, et al. bioRxiv [Preprint]. 2024 Mar 26:2024.02.12.579184. doi: 10.1101/2024.02.12.579184. bioRxiv. 2024. PMID: 38405985 Free PMC article. Preprint.
Label-Free Techniques for Probing Biomolecular Condensates.
Ibrahim KA, Naidu AS, Miljkovic H, Radenovic A, Yang W. Ibrahim KA, et al. ACS Nano. 2024 Apr 23;18(16):10738-10757. doi: 10.1021/acsnano.4c01534. Epub 2024 Apr 12. ACS Nano. 2024. PMID: 38609349 Review.
Sacubitril/valsartan for the treatment of non-obstructive hypertrophic cardiomyopathy: An open label randomized controlled trial (SILICOFCM).
Velicki L, Popovic D, Okwose NC, Preveden A, Tesic M, Tafelmeier M, Charman SJ, Barlocco F, MacGowan GA, Seferovic PM, Filipovic N, Ristic A, Olivotto I, Maier LS, Jakovljevic DG; SILICOFCM Investigators. Velicki L, et al. Eur J Heart Fail. 2024 Jun;26(6):1361-1368. doi: 10.1002/ejhf.3291. Epub 2024 May 27. Eur J Heart Fail. 2024. PMID: 38800948 Clinical Trial.
Between May 2018 and October 2021, 354 patients were screened for eligibility, 115 patients (mean age 58 years, 37% female) met the study inclusion criteria and were randomly assigned to sacubitril/valsartan (n = 79) or control (n = 36). At 16 weeks, there was no si …
Between May 2018 and October 2021, 354 patients were screened for eligibility, 115 patients (mean age 58 years, 37% female) met the study in …
Results of EAHP's 2023 shortages survey.
Miljković N, Polidori P, Leonardi Vinci D, Kuruc Poje D, Makridaki D, Kohl S, Süle A. Miljković N, et al. Eur J Hosp Pharm. 2024 Dec 30:ejhpharm-2024-004090. doi: 10.1136/ejhpharm-2024-004090. Online ahead of print. Eur J Hosp Pharm. 2024. PMID: 38307707
RESULTS: There were 1497 HP responses to the 2023 survey. While 95% (n=1429) of HPs and 86% (n=127) of OHCPs consider medicine shortages an ongoing problem, 84% (n=48) of PHYs and 68% (n=15) of NRS also agreed. ...More than 60% (n=765) of HPs, 5 …
RESULTS: There were 1497 HP responses to the 2023 survey. While 95% (n=1429) of HPs and 86% (n=127) of OHCPs consider medicine …
222 results